Is Ketamine an Opioid?

No. Ketamine is not an opioid. It's a dissociative anesthetic that works by blocking NMDA receptors in the brain and spinal cord, while opioids like morphine, oxycodone, and fentanyl work by activating mu-opioid receptors. Those are two different receptor systems, two different drug classes, and two different risk profiles. The confusion is understandable — both are used for pain, both are controlled substances, and both show up in the same conversations about hospitals, addiction, and prescription drugs. But pharmacologically, and legally, they're not the same thing, and the distinction has real consequences for how ketamine is prescribed, monitored, and used in clinics today.

Is Ketamine a Narcotic?

Not in the sense clinicians and regulators use the word. "Narcotic" started out as a medical term for opioid drugs specifically — morphine, codeine, heroin, and their synthetic relatives — and the DEA still uses it that way in most of its scheduling language. Ketamine doesn't belong to that family. It's classified as a dissociative anesthetic, and what drugs ketamine is similar to turns out to be a short list — chiefly phencyclidine (PCP) and, to a lesser degree, dextromethorphan at high doses. So when someone asks "is ketamine a narcotic," the accurate answer is no, if you're using the word the way a physician or a DEA scheduling document does.

The word gets muddier in everyday and legal usage, where "narcotic" is sometimes used loosely to mean any controlled substance capable of producing sedation or dependence — a usage that would technically sweep in ketamine along with a long list of unrelated drugs. That looser, colloquial use is where most of the confusion comes from. Clinically, though, the term still means opioid, and ketamine isn't one.

How Ketamine Actually Works

Ketamine's mechanism of action comes down to one main target: the NMDA receptor, a site on nerve cells that responds to the neurotransmitter glutamate. Ketamine blocks that receptor, which is what produces the dissociative, "detached from your surroundings" effect patients report during treatment. That same NMDA blockade is also the leading explanation for ketamine's rapid antidepressant effect — it appears to trigger a burst of glutamate signaling that supports the growth of new connections between neurons, a process thought to happen within hours rather than the weeks typical antidepressants take.

Opioids do something else entirely. They bind to mu-opioid receptors — a separate receptor system found throughout the brain, spinal cord, and gut — which blocks pain signals and triggers a release of dopamine that produces euphoria. That mu-receptor activation is also what suppresses the brainstem's drive to breathe, which is the mechanism behind opioid overdose deaths. Ketamine doesn't touch those receptors at treatment doses, so it doesn't carry that particular failure mode. Two drugs, two separate signaling systems, two very different clinical stories.

Ketamine's DEA Schedule III Status

In the United States, ketamine is a Schedule III controlled substance under the Controlled Substances Act — the same tier as anabolic steroids and some codeine-containing combination products. Schedule III drugs are defined as having a moderate to low potential for physical dependence and a lower abuse potential than Schedule I or II substances, but still enough of a risk to require a prescription and DEA tracking.

Compare that to how opioids are scheduled. Heroin sits in Schedule I, defined as having no accepted medical use and a high potential for abuse. The opioids most tied to the overdose crisis — oxycodone, hydrocodone, fentanyl, morphine — are Schedule II, one tier below heroin, reflecting a high abuse potential paired with legitimate medical uses that require tight prescribing controls. Ketamine sitting a full tier below those drugs isn't a technicality; it reflects a genuinely different risk profile, not just a different name. For the full breakdown of what Schedule III means in practice and how state-level rules layer on top of the federal schedule, see what drug class ketamine falls into.

Why the Distinction Matters for Patients

The opioid-versus-ketamine question isn't just academic — it shapes three things that matter directly to someone considering treatment: dependence risk, physical safety during dosing, and why a clinic recommends ketamine in the first place.

Dependence profile. Ketamine does have a real, documented potential for misuse, which is exactly why it's a controlled substance and why legitimate clinics run structured protocols rather than open-ended prescriptions. But its dependence pattern looks different from opioids. Opioid dependence develops predictably with regular use because of how the drug interacts with the body's own opioid system, and withdrawal can start within hours of a missed dose. Ketamine dependence in a clinical setting is far less common, in large part because treatment protocols use infrequent, spaced dosing — often a handful of sessions over a few weeks, then occasional boosters — rather than the daily dosing pattern that drives most substance dependence. The fuller picture of ketamine's dependence and misuse risk is covered in is ketamine addictive.

Respiratory safety. This is probably the single biggest practical reason the opioid comparison matters. Opioid overdose is almost always a breathing problem — the drug suppresses the brainstem signal that keeps you breathing, and death follows from oxygen deprivation, not from the heart or any other organ failing first. Ketamine, at the subanesthetic doses used in mental-health and pain treatment, largely preserves that breathing drive. Its main cardiovascular effect during dosing is a temporary rise in blood pressure and heart rate rather than suppression, which is a big part of why it has such a long track record as a battlefield and emergency-room anesthetic — administered outside a full operating-room setup precisely because it doesn't carry the same breathing risk as opioid- or barbiturate-based sedation.

Why clinics use it. Ketamine's non-opioid mechanism is a direct selling point for two overlapping patient groups. For mood disorders, it offers a treatment option for people who haven't responded to standard antidepressants, working through a mechanism unrelated to the serotonin systems those drugs target. For chronic pain, it gives prescribers a tool that manages certain kinds of pain — particularly nerve-related pain — without adding to a patient's opioid exposure. That matters for people specifically trying to reduce or avoid opioids, whether because of prior misuse, intolerable side effects, or simply wanting to limit how many opioid prescriptions are active at once. You can browse the specific treatment types clinics offer — infusions, injections, Spravato, and oral programs all share this same non-opioid mechanism, just delivered differently.

Ketamine and the Opioid Crisis

Ketamine's rise as a mental-health and pain treatment has happened alongside two decades of rising opioid overdose deaths in the US, and the timing isn't a coincidence. Part of what has pushed prescribers and health systems toward ketamine — for pain management especially — is a search for options that don't add to a patient's opioid exposure. Emergency departments have studied low-dose ketamine as an alternative or supplement to opioid analgesia for acute pain, and pain clinics increasingly offer ketamine infusions for patients with conditions like complex regional pain syndrome or other neuropathic pain conditions that have proven hard to manage with opioids alone or where a patient wants to reduce opioid use altogether.

None of this makes ketamine risk-free, and it isn't marketed or regulated as an opioid substitute in the way, say, buprenorphine is used specifically to treat opioid use disorder. Ketamine is its own drug with its own risks — dissociation, a real misuse potential, and contraindications your prescriber needs to screen for, all covered in what the safety data actually shows. But in a period when opioid-sparing treatment options are in real demand, ketamine's different mechanism is exactly why it's found a place in both psychiatric and pain medicine that opioids can't fill.

If you're weighing ketamine against how it's typically grouped with other altered-state medicines, it's also worth separating it from the psychedelic conversation it often gets lumped into — ketamine's relationship to psilocybin and MDMA-assisted therapy is a different question from the opioid one, with its own answer.

Frequently Asked Questions

If you're considering ketamine treatment and want to compare providers who offer it for pain or mood conditions, you can search ketamine clinics by state and city and review what each one states about screening, monitoring, and the specific treatments they provide.

Sources: DEA Controlled Substances Act scheduling records, FDA prescribing information for ketamine and esketamine (Spravato), and peer-reviewed pharmacology literature on NMDA-receptor and mu-opioid-receptor mechanisms. Informational only — not medical advice. Talk with a licensed clinician about your health history before starting treatment.